| Supriya Lifescience announced that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the Company's manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026.
The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating “Voluntary Action Indicated (VAI)”, signifying a successful completion of the inspection. |